Abbott (NYSE:ABT) offered additional details on its up-coming split, which will result in a new standalone pharmaceutical and biologics arm dubbed AbbVie.
Pharmaceutical
How to reduce breast cancer risk? Avoid excess imaging, researchers say | MassDevice.com On Call
MASSDEVICE ON CALL — University of California researchers recommended that women be more wary of breast cancer imaging exams, warning that excess testing may increase a women’s risk of developing breast cancer.
Reserachers dug deeper into an Institute of Medicine report on the environmental factors contributing to breast cancer, focusing on radiation exposure tied to breast cancer diagnostic imaging exams.
Funding R&D: High prices, overuse a failed strategy
Much has been written about the travails of the pharmaceutical industry. Generic competition is reducing profitability as leading blockbuster drugs like Pfizer’s Lipitor lose patent protection. Biotech generic competition is on the horizon.
Abbott doles out $1.6B for illegal marketing charges | MassDevice.com On Call
MASSDEVICE ON CALL — Health care giant Abbott Labs (NYSE:ABT) agreed to a guilty charge and $1.6 billion in criminal and civil fines for charges of illegal marketing for Depakote, part of the pharmaceutical business the company plans to separate from its medical products arm.
The Massachusetts House of Representatives has voted to repeal the Pharmaceutical and Medical Device Manufacturer Conduct Law
by Ingrid A. Pelzer
The Massachusetts House of Representatives recently voted on and passed its proposals for the commonwealth’s Fiscal Year 2013 budget. The proposal included Consolidated Amendment I, which would repeal the Pharmaceutical and Medical Device Manufacturer Conduct Law [Mass. Gen. Laws Ch. 111N].
Feds to new J&J CEO Gorsky: Testify | MassDevice.com On Call
IBM’s Watson supercomputer tackles cancer | MassDevice.com On Call
MASSDEVICE ON CALL — IBM’s Jeopardy-winning Watson supercomputer is taking a swing at oncology research in efforts to help hospitals more quickly diagnose and treat cancer.
Watson can cull through 200 million pages of information in less than 3 seconds, according to IBM, and the machine is getting an education in oncology at Manhattan’s Memorial Sloan-Kettering Cancer Center.
J&J’s cred fades for 1st time in 13 years | MassDevice.com On Call
MASSDEVICE ON CALL — Incoming Johnson & Johnson (NYSE:JNJ) CEO Alex Gorsky will have a full plate when he takes the corner office in April.
Amid ongoing recalls and related lawsuits, Gorsky has his work cut out for him in restoring consumer faith in health care giant.
White House budget to cut health funding by $360 billion | MassDevice.com On Call
MASSDEVICE ON CALL — The White House’s budget proposal is expected to cut $360 billion in health care spending over the next 10 years, according to a budget summary released last week.
That bulk of the cuts, $300 billion, will come from Medicare programs.
The proposal has changed little since President Barack Obama released the initial $3 trillion savings plan in September, Healthwatch reported.
McKesson’s Q3 beats The Street, pays $918M for Canadian pharmacy biz | Earnings Roundup
McKesson (NYSE:MCK) shares got a bump in after-hours trading yesterday when it reported strong 3rd-quarter results and announced the $918 million acquisition of a chain of independent pharmacies in Canada.
MassDevice.com +3 | Philips takes another shot at Zoll over patents, Discredited vaccine-autism doc sues critics and fewer mergers but higher pricetags in 2011
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.